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 ABSTRACT 
Background. Since the discovery of the cannabinoid receptors, numerous studies associate the 
endocannabinoid system with several physiological and pathological processes including cancer, 
appetite, fertility, memory, neuropathic and inflammatory pain, obesity, and neurodegenerative diseases. 
Over the last two decades, several researches have been dedicated extensively on the cannabinoid 
receptors ligands since the direct activation of cannabinoid receptors results in several beneficial effects, 
in the brain and in the periphery. 
Methods. The cannabinoid CB1 and CB2 receptor synthetic ligands reported in this review have been 
collected by a wide research of scientific literature in particular in public database for patents and 
clinical trials. The references for patent numbers, clinical trial registry numbers, websites and scientific 
articles are reported in the reference section. 
Results. During past years, cannabinoid CB1 and CB2 receptor ligands from plants or lab were rapidly 
developed and then various new structures were reported to be cannabinoids. However the CB1 
receptor ligands have had a limited usefulness due to their psychotropic effects, dependence, and 
cognitive impairment. On the contrary the development of CB2 receptor ligands has been more 
productive. Furthermore peripherally restricted agonists as well as CB1 receptor positive or negative 
allosteric modulators were studied with the aim of eliminating the undesirable CB1 receptor central 
effects. 
Conclusions. The CB1 and CB2 receptor ligands offer several therapeutic opportunities for several 
CNS-related diseases. Based on the scientific literature, this review provides an overview of CB1 and 
CB2 receptor synthetic ligands obtained from drug research and in particular those synthesized for 
therapeutic purposes and potential clinical applications for central nervous system disorders. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
For many centuries, preparations from Cannabis sativa L have been used as popular recreational drug  
as well as for their  therapeutic effect, however the chemical and biological bases of their 
pharmacological effects are still not fully understood. Cannabis plants produce large number of related 
compounds called phytocannabinoids, of which Δ9-tetrahydrocannabinol (Δ9-THC, Fig.1) is the 
principal bioactive component. This compound was identified and synthesized in the 1960s [1]
 
and, it 
was used as model for synthesizing analogues with very potent medical properties. However the new 
compounds showed psychotropic side effects and in several cases the pharmacological mechanisms of 
action were not well-identified. Particularly important was the identification of the cannabinoid 
receptors (CB1 and CB2 receptors) followed by the discovery of their endogenous ligands 
and of different enzymes involved in their biosynthesis and biotransformation that allowed to deepen 
the knowledge of endocannabinoid system (ES) and the clinical applicability of cannabis-based 
treatments [2]. 
The CB1 and CB2 receptors are members of the G protein-coupled receptor (GPCR) family. They are 
characterized by an N-terminal extracellular domain that possesses glycosylation sites, a C-terminal 
intracellular domain coupled to a G protein complex, and seven hydrophobic transmembrane segments.  
The cannabinoid receptors are expressed in many species, including human. Initially, it was 
hypothesized that CB1 receptor was localized generally in the brain whereas CB2 receptor was 
restricted in immune cells such as leucocytes and those of the spleen and tonsils [3]. However, CB1 
receptor has recently been found also in peripheral tissues, whereas CB2 receptor was identified also in 
the central nervous system, e.g. in the microglial cells. The human CB2 receptor has 44% amino acid 
sequence identity with CB1 receptor for all protein and 68% similarity for the transmembrane domains. 
The cannabinoid receptors are coupled with Gi or Go protein, positively to mitogen-activated protein 
(MAP) kinase and negatively to adenylyl cyclase, thus reducing the production of cAMP [3]. 
CB1 receptor also modulates ion channels, resulting, for example, in the inhibition of P/Q- type 
voltage-sensitive Ca
2+
 channels. Inhibition of presynaptic calcium channels by cannabinoids likely 
reduces neurotransmitter release from CB1 receptor-expressing presynaptic terminals. One of the 
functions of cannabinoid receptors in the immune system is modulation of cytokine release. Activation 
of B- and T-cell CB2 receptor by cannabinoids inhibits adenylyl cyclase in these cells and reduces the 
immune response. 
Experiments utilizing CB1 and CB2 receptors knockout mice indicate  the presence of further  
cannabinoid receptors such as GPR18, GPR55, and GPR119 [4,5].
 
The latter is involved in the 
regulation of metabolism [6] and body weight [7]. GRP55 [8,9] and GPR18 [10] regulate the   
activation of microglia and the neuropathic pain. Finally the TRPV1 receptor is involved in pain and 
inflammation and is regulated by cannabinoids [11]. For these reasons these receptors may be 
interesting targets for the treatment of neuroinflammation and neuropathic pain. 
Cannabinoid receptors are localized in the presynaptic junction and are activated by lipid mediators 
called endocannabinoids. At the present moment, the most bioactive and best characterized 
endocannabinoids are anandamide (arachidonylethanolamide; AEA) (Fig.1) and 2-
arachidonoylglycerol (2-AG) (Fig. 1), however the family of endocannabinoids  comprises also noladin 
ether virodhamine,  N- arachidonoyl dopamine (NADA), and other  compounds such as 
palmitoylethanolamide (PEA) and oleoylethanolamide (OEA)  (Fig.1). Unlike many other 
neurotransmitters, endocannabinoids are produced upon demand, are biosynthesized 
from integral constituents of cellular membrane by action of some enzymes and have a moderately 
slow time frame of action. 
The endocannabinoid signaling is terminated by cellular reuptake and their enzymatic hydrolysis. There 
is only pharmacological evidence of the existence of reuptake transporter of endocannabinoids [12]. On 
the contrary, the enzymes involved in the metabolism of endocannabinoids are better known. 2-AG is 
degraded by the monoacylglycerol lipase (MAGL) giving arachidonic acid and glycerol [13] and  fatty 
acid amide hydrolase (FAAH) degrades AEA to arachidonic acid and ethanolamine [14]. 
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Figure 1. Chemical structures of Δ9-THC and endocannabinoids. 
 
During past years, cannabinoid compounds from plants or lab were rapidly developed and then various 
new structures were reported to be cannabinoids. Cannabinoids receptors have an important role 
in controlling of cell fate and then they represent an attractive for novel drug development [15,16]. 
Recently various researches reported that natural and synthetic cannabinoids showed an important 
antitumor activity in preclinical trials, they could inhibit cell proliferation, induce apoptosis and block 
angiogenesis [17]. Nabilone (Cesamet) (Fig. 2), synthetic analog of Δ9-THC, is an example of 
cannabinoid-based drugs; this compound is a potent CB1/CB2 agonist, and at this time is used for the 
treatment of chemotherapy-induced nausea and vomiting in humans. Synthetic analogs of Δ9-THC, 
such as n-hexyl- Δ6a-THC (Fig. 2), 1,2-dimethylheptyl-THC (Fig. 2), HU-210 (Fig. 2) levonantradol 
(CP 50,556-1) (Fig. 2)  and nabitan (Fig. 2), were initially tested, but none of these were introduced in 
the market. Furthermore, in different research model cannabinoid ligands showed to inhibit pain via the 
CB1 or/and CB2 receptor. For example the phase II studies of NIH (http://clinicaltrials.gov) regarding 
the CB2 receptor agonist GW842166X (Fig. 6 ) [18], indicated that this compound possesses analgesic 
effect in dental surgery and in the treatment of osteoarthritis pain of the knee. Besides cannabinoids are 
related to hepatic pathological conditions and to many other diseases such as osteoporosis and atopic 
dermatitis [19,20]. Finally some researches on neurological diseases demonstrated that cannabinoids 
should be used to slow the progression of neurodegenerative disorders [21] such as Huntington’s 
disease [22], Alzheimer’s disease [23], Parkinson’s disease [24] and multiple sclerosis [25] (Table 1). 
For these reasons cannabinoid receptor could be considered new targets for neuropsychiatric and 
neurodegenerative disorders.  
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Figure 2. Chemical structures of synthetic analogs of Δ9-THC 
 The CB1 and CB2 ligands could be classified as agonists, antagonists and inverse agonist. The agonist 
produce an increase in the basal level of signaling after binding to the receptor; the inverse agonists 
down regulate the signaling while the antagonists stop the agonists or the inverse agonists modulating 
the receptors. Furthermore ligands able to modulate ES by binding to allosteric sites (positive, negative, 
and silent allosteric modulators) were developed [26]. 
 
Table 1. Examples of cannabinoid receptor ligands and their potential use for specific CNS disorders 
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ROLE OF THE ENDOCANNABINOID SYSTEM IN THE PATHOPHYSIOLOGY OF CNS 
DISORDERS 
In the last 10–15 years, several preclinical and clinical studies have been reported in the literature, 
demonstrating that ES-targeting compounds exert neuroprotective effects through an array of different 
mechanisms [27]. Cannabinoids may achieve better therapeutic outcomes compared to classic 
neuroprotective agents due to their multi-target modulation. Indeed neurodegenerative disorders are 
generally characterized by different cytotoxic events such as energy failure, excitotoxicity, 
mitochondrial dysfunction, inflammation, failures in proteostasis, and oxidative stress. Compounds 
acting on the ES exhibit a wide spectrum of activity as they can modulate different molecular targets 
that might lead to a synergistic neuroprotective effects [28]. They comprise not only the activation of 
cannabinoid receptors but also CB receptor-independent mechanisms, such as the blockade of NMDA 
receptors, or the activation of nuclear receptors as the PPARs [29]. 
The CB1-mediated neuroprotective effects apparently occur at two specific neuronal sites: presynaptic 
glutamatergic neurons where CB1 receptor activation leads to a reduction of glutamate release and 
postsynaptic CB1 receptor on NMDA-expressing neurons, where CB1 activation prevents an excessive 
intracellular Ca
2+ 
concentration by closing voltage dependent calcium channels [29]. Another 
neuroprotective effect mediated by CB1 receptor activation consists in improving the blood circulation 
in case of injured brain, which is particularly important in stroke or traumatic injuries [30]. In particular 
for this protective effect, recent evidence indicates the involvement of CB2 receptor [31]. 
The CB2-mediated effects occur in activated microglial cells, astrocytes, oligodendrocytes and in some 
restricted neuronal subpopulations [29]. In particular, CB2 receptor show an important role in the 
proliferation and migration of microglia cells to the lesion sites [32] and reducing the production of 
neurotoxic factors (e.g. tumor necrosis factor-α (TNF-α)) [29]. The modulation of astrocyte activity for 
a damage to brain, involves CB1 receptor [29] and appears to be associated with an increased 
production of metabolic substrates such as lactate or ketone bodies [33], neurotrophins and anti-
inflammatory mediators that can limit the neuronal damage. Furthermore the activation of CB2 
receptor could also inhibit the production of pro-inflammatory  chemokines (e.g., fractalkine) by 
astrocytes. Finally, CB2 receptor has been also identified in oligodendrocytes which play a crucial role 
in modulating neuronal activity [34].  
Cannabinoids in Parkinson’s disease. Parkinson’s disease (PD) is a neurodegenerative condition that 
affects dopaminergic neurotransmission in the basal ganglia resulting in hypokinesia. The ES regulates 
neurotransmitter release [35] and motor activity [36], thus representing a promising target for treatment 
of motor dysfunction. The neuroprotective effects can be associated either to the activation of CB2 
receptor which exert anti-inflammatory effects or the blockade of CB1 receptor which improve motor 
activity. In addition, the combination of antioxidant agents with agonists for alternative AEA targets, 
such as PPARs, showed beneficial effects in animal models of PD [37]. In particular, preclinical studies 
proved that low doses of the CB1 receptor antagonist rimonabant, decrease hypokinesia in an animal 
model of PD [38]. Moreover Δ9-THC and CBD showed to protect nigrostriatal dopaminergic neurons 
from the neurotoxin 6-hydroxydopamine exerting antioxidant action [39]. Therefore the CBD/ Δ9-
THC-based medicine Sativex
®
  may deserve further clinical investigation in PD. 
Cannabinoids in Alzheimer’s disease. Alzheimer’s disease (AD) is an aging-related 
neurodegenerative disease characterized by the progressive deterioration of cognition and memory.  It 
was reported that changes in the endocannabinoid signaling occur during the progression of AD, 
particularly in the hippocampus and cerebral cortex. The increase of 2-AG levels and upregulation of 
CB2 receptors in microglial cells may exert some protective effects against β-amyloid-induced 
neuroinflammation and neuronal injury [40] especially in plaque-bearing areas [41]. On the other hand, 
the downregulation of CB1 receptor expression in hippocampus and basal ganglia may contribute to the 
destructive inflammatory process which accompanies AD progression [41]. In addition, the increased 
FAAH activity, especially in astrocytes, can lead to the formation of more arachidonic acid eventually 
leading to pro-inflammatory effects. However, it was shown that Δ9-THC can counteract β-amyloid 
aggregation and the consequent plaque formation by inhibiting acetylcholinesterase activity [42]. In 
addition, Δ9-THC can reduce the plaque density by increasing the expression of neprilysin, which is 
one of the key enzymes involved in the β-amyloid degradation cascade. Sativex® was in recent times 
investigated in a preclinical model of AD. The results showed a reduced gliosis, oxidative stress, tau- 
and β-amyloid aggregation and the induction of autophagy [43]. Dronabinol, a synthetic preparation of 
Δ9-THC, is used as antiemetic and appetite-stimulator in AD patients [44]. Furthermore in patients with 
severe AD, Δ9-THC also showed to reduce agitation which is a hallmark of disease progression [45]. 
Cannabinoids in Huntington’s disease. Huntington’s disease (HD) is a chronic progressive disorder 
caused by the dysfunction of huntingtin. In HD, the gene encoding for this protein has an excessive 
number of cytosine-adenine-guanine triplet repeats (CAG) leading to the biosynthesis of a non-
functional protein. In animal models of HD, it was demonstrated that the activation of a restricted CB1 
receptor population in cortical glutamatergic neurons protects these cells from death [46]. Furthermore, 
CB2 receptor activation showed positive effects by reducing chronic inflammation and activation of 
microglia cells in different rodent models of HD [47]. Recently, the combination of CBD and Δ9-THC 
(Sativex
®
) was tested on HD patients in a phase II clinical trial [48] to assess the therapeutic potential 
of activating CB receptors in this chronic inflammatory disease. The results showed that Sativex
®
 was 
safe and well tolerated in HD patients, but unfortunately, the drug did not show any significant 
reduction of disease progression [48].  
Cannabinoids in Epilepsy. Cannabis has been used as a folk medicine for millennia such as for the 
treatment of neurological disorders (e.g. epilepsy). The exact targets that mediate the anti-seizure 
effects of cannabinoids are still unknown. Several cannabinoids bind and modulate multiple brain 
targets beside cannabinoid receptors such as the transient receptor potential cation channel (TRPV1-3), 
glycine receptor alpha (3GlyR), peroxisome proliferator-activated receptor gamma (PPAR-), 
calcium-gated ion channel (Cav3 ion channel). Several studies have examined the effects of cannabis in 
epilepsy but generally they had methodological problems such as the lack of placebo-controlled studies 
[49]. A clinical trial, initiated in 2013 on children and young adults with severe epilepsy, assessed the 
therapeutic potential of a pharmaceutical preparation, named Epidiolex
®
, composed by purified 
cannabis extracts containing 99% of CBD and less than 0.1% of Δ9-THC. A preliminary report showed 
that 54% of patients (74 out of 137) who had received the treatment for 12 weeks, experienced a 
significant reduction in the number of seizures [50]. Two additional clinical trials are currently on-
going for the evaluation of Epidiolex
®
 in two forms of severe, childhood-onset epilepsy [51,52]. 
 
CANNABINOID RECEPTOR AGONIST 
CB1 receptor agonists 
Δ9-THC (Fig. 1), the psychotropic component of cannabis, acts as a CB1 receptor partial agonist with 
modest affinities for both cannabinoid receptors. Instead the nonpsychotropic compounds of cannabis, 
tetrahydrocannabivarin (Fig. 3) and cannabinol (Fig. 3), behave as weak antagonist and agonist for CB1 
receptor respectively, whereas show modest agonist activity for CB2 receptor. Cannabidiol (Fig. 3) and 
cannabidivarin (Fig. 3) without psychotropic activity, exhibit very low affinities for both cannabinoid 
receptors, and the mechanism through which cannabidiol acts is not clear. Δ9-THC (Dronabinol, 
Marinol) in the United States is approved for treatment of nausea and vomiting in patients receiving 
chemotherapy and for treating anorexia related to weight loss in patients with AIDS [53]. Furthermore 
it decreases neuropathic pain associated with multiple sclerosis [54] and is useful as an antiemetic agent. 
The oromucosal spray combination of Δ9-THC and cannabidiol (Sativex, Nabiximols) is used in 
treating multiple sclerosis-related spasticity [55] and pain in patients with advanced cancer [56]. The 
same combination showed to protect nigrostriatal dopaminergic neurones from the neurotoxin 6-
hydroxydopamine via an antioxidant action indicating to be a possible candidate for clinical 
investigation in Parkinson’s disease [39].  
The CB1/CB2 agonist, HU-210 (Fig. 2) prevents amyloid-beta (Aβ)-induced increases in microglia 
activation and TNF-α release [41]. In Alzheimer’s disease the activation of CB1 receptor induces the 
modulation of several inflammatory cytokines [57],
 
whereas the stimulation of CB2 receptor suppresses 
microglial activation and subsequent production of TNF-α and nitric oxide [58]. The synthetic 
cannabinoid, HU-211 (Dexanabinol) is the enantiomer of HU-210; it does not act as a cannabinoid 
receptor agonist, but instead has NMDA receptors antagonist effects and thus it protects cells from 
NMDA induced neurotoxicity mimicking the results of the current drug memantine, a noncompetitive 
antagonist of the N-methyl D-aspartate (NMDA) receptor approved by the Food and Drug 
Administration (FDA), and improving symptoms [59].   
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Figure 3. Chemical structures of phytocannabinoids  
 
(R)-Methanandamide also known as AM356 (Fig. 4) is an anandamide analog substituted with a chiral 
methyl group. It showed a significantly higher metabolic stability and CB1 receptor potency [60]. 
AM356 inhibited the LPS-induced release of interleukin-1 beta and tumor necrosis factor-alpha from 
microglia and could be useful for patients with severe traumatic brain injuries as well as 
neurodegenerative diseases which are associated with neuroinflammation [61]. 
Aminoalkylindole derivatives represent the first distinct class of compounds that differ from the natural 
cannabinoids. This class contains pravadoline (Fig. 4) and its very potent CB1/CB2 receptors agonist 
analog WIN 55212-2 (Fig. 4), which is usually used as pharmacological probe. WIN 55212-2 showed 
to reduce neuronal death and infarct volumes in a CB1 receptor-dependant manner [62]. Other 
important aminoalkylindole derivatives are AM678 (JWH-018) (Fig. 4) and AM2201 (Fig. 4) that 
exhibited antinociceptive properties, and Org 28611 (Fig. 4) which was tested in humans both as an 
analgesic and a sedative [63]. In particular AM678 is a CB1 and CB2 receptors agonist with a higher 
affinity than Δ9-THC and it shares with the active ingredient of Marijuana, CB1-dependent reinforcing 
and dopamine stimulant actions [64]. However many aminoalkylindole derivatives have been classified 
as Schedule 1 Controlled Substances  and has been detected in several samples of a smokable herbal 
mixture termed "Spice", marring their therapeutic value [65]. 
Among the indanyl-4-oxy derivatives reported in literature as cannabinoid receptors ligands, KN38-
72717 (BAY 38–7271) (Fig. 4) showed to be selective and highly potent cannabinoid CB1/CB2 
receptors agonist with neuroprotective efficacy in traumatic brain injury animal model [66]. Recently 
this compound showed a significant, dose-dependent and long-lasting reduction of cortical lesion sizes 
due to occlusion of the middle cerebral artery (eMCAO) and appeared beneficial in the acute early 
phase of the comatose patient after a head injury [67].  
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Figure 4. Chemical structures of CB1 receptor agonists  
 
Many authors reported that the activation of CB1 receptor has potential to serve for therapeutic 
attenuation of degeneration in select CNS disorders [68-70]. Unfortunately the activation of this 
receptor also engenders psychotropic effects, dependence, and cognitive impairment [71-73]. Recently 
with the aim to eliminate the undesirable CB1 central effects, peripherally restricted agonists were 
developed. This study has led to the discovery of naphthalen-1-yl-(4-pentyloxynaphthalen-1-
yl)methanone, SAB378 (Fig. 5), which shows good oral bioavailability, potent antihyperalgesic activity, 
and limited brain penetration [74]. In addition, the quinazoline derivative SAD448 (Fig. 5) was 
identified as highly polar CB1 agonist that showed to be analgesic in inflammatory and neuropathic 
pain models. These compounds demonstrated to control spasticity in a multiple sclerosis model via 
action on the peripheral nerve CB1 receptor [75]. Furthermore the imidazol derivatives AZD1940, 
AZD1704 and AZ11713908 when administered orally have produced analgesia effect in rodent models 
of acute, inflammatory and/or neuropathic pain through the activation of peripheral CB1 receptor [76]. 
In particular AZD1940 (Fig. 5) was studied as candidate drug for treatment of neuropathic pain and it 
has undergone evaluation in humans [77].  
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Figure 5. Chemical structures of peripherally restricted CB1 receptor agonists 
 
CB1 receptor allosteric modulators 
CB1 positive or negative allosteric modulators represent interesting prospects for developing CB1 
receptor ligands lacking CB1-related undesirable side effects. Allosteric modulators offer several 
advantages, in fact they show greater subtype selectivity for the higher sequence divergence at 
extracellular allosteric binding sites, respect to the conserved orthosteric domains. Furthermore 
allosteric modulators have tissue selectivity, because they exert effects only where endogenous ligands 
are present. Among allosteric modulators recently reported, the compounds Org27569 (Fig. 6) [78] and 
PSNCBAM-1 (Fig. 6) [79] have been more widely studied. Org27569 enhances CB1 receptor binding 
of CP55,940, but on the contrary it behaves as an negative modulator for receptor activation in several 
biochemical assays. In vivo, Org27569 did not produce any cannabimimetic effects alone. Similar to 
the blockage of the orthosteric binding site, Org27569 reduced food intake, but unlike SR141716A, its 
effects resulted CB1-independent [80]. In another study, the anorexic effect of Org27569 developed 
tolerance after 4 days of daily administration at the dose of 5.6 mg/kg. The effect on body weight gain 
lasted for 10 days after the cessation of drug treatment [81]. Another study showed that Org27569 
induced a dose-dependent (1-5.6 mg/kg) diminution of both cue- and drug-induced reinstatement of 
cocaine- and methamphetamine-seeking behaviour. In the same model, SR141716A exhibited similar 
inhibitory actions on reinstatement of drug-seeking, suggesting a CB1-mediated mechanism [82]. 
Altogether, these data suggest that Org27569 may not function as an efficient CB1 receptor allosteric 
modulator in vivo, although the negative allosteric modulation might deserve further investigations as a 
potentially treatment for drug addiction.  
Recently it was shown that pregnenolone levels (Fig. 6) increase in the brain upon CB1 receptor 
activation. In vitro and in vivo, pregnenolone partially counteracted some of the Δ9-THC-mediated 
central effects, including hypothermia, catalepsy, hypomotility, analgesia and food intake. Despite 
pregnenolone exhibited a mild negative allosteric modulation of CB1 receptors, it rather behaved as a 
signaling-specific inhibitor for CB1-mediated signaling, reducing several effects of Δ9-THC. This 
negative feedback mechanism suggests that pregnenolone might act as an endogenous protector against 
excessive CB1 receptor activation in the brain, thus offering a potential novel therapeutic approach for 
the treatment of cannabis addiction [83]. Pregnenolone is not a druggable molecule because of its 
conversion into other steroids and the very poor bioavailability, therefore Aelis Farma is developing a 
new pharmacological class of pregnenolone derivatives C3-17,NMPDs (Non Metabolized 
Pregnenolone Derivatives) which have a good bioavailability and are not converted into other steroids  
[84]. Pepcans (pepcan endocannabinoids) are a family of N-terminal extended endogenous peptides 
which spans from 12 to 23 aminoacids and derive from the -chain of hemoglobin. The shortest 
member of the family, pepcan-12 is the most potent and efficacious NAM (negative allosteric 
modulator) at CB1 receptors and showed to non-competitively reduce the binding and functional 
activity of endogenous and synthetic CB1 orthosteric agonists [85]. Localization studies identified 
distinct biosynthetic/releasing sites for pepcan-12 in the periphery (adrenal medulla) and in the brain 
(locus ceruleus) [86]. Striker et al. investigated the different CB1 allosteric modulators for the ability to 
modulate the 2-AG-mediated depolarization-induced suppression of excitation (DSE) as a model to test 
CB1 modulators in a neuronal model of endogenous cannabinoid signaling. Interestingly, PSNCBAM-
1, Org27569 and pepcan-12 were the only compounds to confirm a negative allosteric modulation of 
the 2-AG-induced DSE [87]. The first pharmacological evidence demonstrating the effectiveness of a 
positive allosteric modulator (PAM) at CB1 receptor was shown for the endogenous anti-inflammatory 
mediator, lipoxinA4 (Fig. 6), which was found to enhance the pharmacological effects of AEA at the 
CB1 receptors both in vitro and in vivo. Furthermore, lipoxinA4 showed protective effects in mice 
against β-amyloid (1-40)-induced impairment in learning and memory [88]. Ignatowska-Jankowska et 
al. recently described a new allosteric modulator for CB1 receptors, ZCZ011 (Fig. 6) which enhances 
orthosteric agonist effects, thus behaving as a positive modulator (PAM) [89]. In mice, ZCZ011 
improved the potency of different orthosteric agonists in behavioural tests indicative of cannabimimetic 
activity, including antinociception, hypothermia, catalepsy, locomotor activity, and in the drug 
discrimination paradigm. Administration of ZCZ011 alone devoid any activity, but elicited CB1-
mediated antinociceptive effects in a model of neuropathic and inflammatory pain, thus suggesting that 
CB1 PAMs might be used to treat pain without producing unwanted cannabimimetic side effects.  
Altogether, the pharmacological profile of CB1 allosteric modulators is very complex and further 
investigations are warranted to clearly identify the potential therapeutic exploitation for this new class 
of compounds. 
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Figure 6. Chemical structures of CB1 receptor allosteric modulators 
 
 
CB2 receptor agonists 
In the last years the development of CB2 receptor ligands as potential drugs is increased since they are 
devoid of the psychotropic side-effects associated with the activation of CB1 receptor. Under normal 
homeostatic conditions the CB2 receptor is almost entirely peripheral where exhibits antinociceptive 
and anti-inflammatory activity. Moreover CB2 receptor is up-regulated in inflamed tissues associated 
with CNS disorders and, when activated, it is important in regulating neural inflammation and 
neurogenesis properties. These considerations caused a great development of CB2 receptor selective 
agonists and initially some aminoalkylindoles resulted very effective. One of them AM1241 (Fig 7) 
showed important results when tested in rodent models for neuropathic and inflammatory pain [26]. 
More importantly, it was reported that daily injections of AM-1241 in animal models of ALS increase 
the survival interval after disease onset by slowing motor neuron degeneration [90].  
The non-selective cannabinoid receptor agonist WIN55,212-2 (Fig. 4) protects mouse nigrostriatal 
neurons from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity and 
neuroinflammation by inhibiting microglial activation/infiltration  suggesting that CB2 receptor might 
be a new therapeutic target to slow the degenerative process in Parkinson disease [91]. Furthermore 
WIN 55212-2 showed to reduce the differentiation of T cells into Th1 effector cells, thereby reducing 
the production of inflammatory mediators and disease severity in a viral model of multiple sclerosis 
[92].
 
Finally the same compound in an animal model of Alzheimer’s disease, prevents Aβ-induced 
cognitive impairment and neuronal loss [41].  
Regarding synthetic analogs of Δ9-THC, JWH-133 (Fig. 7), a CB2-specific agonist, showed to reduce 
dose-dependently hyperalgesia in an autoimmune encephalomyelitis mouse model of multiple sclerosis 
promoting CB2 receptor as a possible target for the treatment of central pain in multiple sclerosis [93].  
The same compound demonstrated to ameliorate several parameters in Alzheimer's disease such as 
decreased memory and learning, neuroinflammation, oxidative stress damage and oxidative stress 
responses, selected tau kinases, and tau hyperphosphorylation around plaques; on the contrary, the 
chronic treatment with JWH-133 was ineffective for the amyloid-β production or deposition in cortex 
and hippocampus [94]. Finally the selective agonist HU-308 (Fig. 7) was used to show the benefic 
effects of CB2 receptor activation for stimulation of microglial cells, infiltration of macrophages and 
also certain capability of these cells to generate proinflammatory factors in animal model of Parkinson 
inflammation [95].  
During the early 2000s 1,8-naphthyridin-4(1H)-on-3-carboxamide derivatives were reported as novel 
cannabinoid ligands [96]. Successively 1,8-naphthyridin-2(1H)-on-3-carboxamide derivatives were 
reported as potent and selective CB2 receptor ligands.  The concentration–dependent inhibitory action 
on human basophils activation and the concentration-dependent decrease of cell viability in Jurkat cells 
shown by N-(4-methylcyclohexyl)-1-benzyl-1,8-naphthyridin-2(1H)-on-3-carboxamide (CB74) (Fig. 7)  
indicate that this compound possess agonist properties on CB2 receptor [97]. Recently the same 
compound showed to inhibit cell activation markers in multiple sclerosis patient derived lymphocytes 
more efficiently than in healthy control derived cells [98]. Indeed, this derivative reduced the levels of 
Cox-2 in lymphocytes from patients whereas no effect was observed in control cells [98]. The 
structural analogue CB91 (Fig. 7) showed to modulate the immune response of peripheral blood 
mononuclear cells (PBMC) acting with a CB2 receptor mediated mechanism [99]. Furthermore CB91 
showed medium level of BBB permeability that may be looked-for to maintain its beneficial effects on 
infiltrating lymphocytes at the levels of the CNS [99]. The obtained findings suggest potential 
application of these compounds in neuroinflammation, suggesting the necessity of further 
investigations of their effects in the therapy of multiple sclerosis. Very interesting, recently it was 
demonstrated that the substituent at C-6 position of the central nucleus of this class of compounds is 
crucial for the functionality identifying it as the key molecular feature that discriminates 1,8-
naphthyridin-2(1H)-on-3-carboxamide agonists from antagonists/inverse agonists [100]. 
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Figure 7. Chemical structures of CB2 receptor agonists 
 
Recently a new class of indazoles was developed  with a specific multi-target profile that is a promising 
approach against multifactorial illnesses as Alzheimer’s disease. In particular 1-(2-
diisopropylaminoethyl)-3-(4-methoxybenzyloxy)indazole (3) (Fig. 7)  and 5-Amino-3-(2-
naphthylmethoxy)-1-(2-piperidinoethyl)indazole (24) (Fig. 7) behave as CB2 receptor agonists and 
simultaneously show inhibition of butyrylcholinesterase (BuChE) activity, related to the loss of 
episodic memory, with antioxidant properties suggesting that these compounds can be regarded as a 
potential agent useful for Alzheimer’s disease [101].  
A novel resorcinol-based compound O-1966 (Fig. 7) was reported as selective CB2 receptor ligand that 
attenuated both chronic and remitting-relapsing autoimmune encephalomyelitis and reduced rolling and 
adhesion of endogenous leukocytes to pial microvasculature in experimental animal model suggesting 
that pharmacological CB2 receptor ligands offer a new strategy for BBB protection during 
neuroinflammation [102]. Furthermore the repeated treatment with this CB2 agonist determined 
positive effects on blood-brain barrier integrity and neuronal degeneration in mice with traumatic brain 
injury [102]. 
Tricyclic pyrazoles represents a new class of highly selective CB2 receptor agonist. Among them Gp1a 
(Fig. 7) showed a positive effect on experimental autoimmune encephalomyelitis animal model that has 
similarities to human MS, through two different mechanisms: an initial effect on Th1/Th17 
differentiation in peripheral immune organs, and a later effect on the accumulation of pathogenic 
immune cells in the CNS, connected to reduction of chemokines and adhesion molecules [103]. These 
results indicate the importance of CB2 selective ligands as potential therapeutic agents in 
neuroinflammation.
  
Several CB2 ligands of miscellaneous structure isolated from different natural sources have been 
described. Among them, β-caryophyllene (Fig. 8), which is a major sesquiterpenoid constituent of 
cloves (Syzygium aromaticum L.) and of the essential oils of numerous plants, including hemp 
(Cannabis sativa L.), exhibited a nanomolar potency in binding and activating CB2 receptors in vitro 
and in vivo [104]. β-Caryophyllene showed CB2-mediated beneficial effects in animal models of 
inflammation , anxiety, depression and neurodegenerative diseases [105-107]. β-caryophyllene has 
been patented for the treatment of schizophrenia [108]. Several derivatives of β-caryophyllene have 
been recently shown to retain the binding properties to CB2 receptors and acquiring new interesting 
pharmacological features which might lead to synergistic effects in vivo [109]. 4′-O-methylhokiol 
(MH) (Fig. 8) is a relatively simple biphenyl scaffold which is the major bioactive constituent of 
Magnolia grandiflora L. seed oil. MH showed to potently and selectively activate CB2 receptors [110] 
and to exert pronounced anti-inflammatory, anti-osteoclastogenic, and neuroprotective effects in vivo 
[111-113]. MH was patented as a potential treatment for inflammatory diseases [114], dementia [115] 
and preventing amyloid-related diseases [116]. Finally, the alkylamides dodeca-2E,4E,8Z,10Z-
tetraenoic acid isobutylamide (A1) and dodeca-2E,4E-dienoic acid isobutylamide (A2) (Fig. 8) which 
have been isolated from Echinacea purpurea and Echinacea angustifolia, were shown to bind to and 
activate CB2 receptors more strongly than the endogenous cannabinoids with Ki values in the low 
nanomolar range [117]. In cellular systems and in human blood, these alkylamides potently inhibited 
lipopolysaccharide-induced inflammation and exerted modulatory effects on cytokine expression 
[117,118]. Echinacea extracts were patented for potential therapeutic uses and several clinical trials 
testing alkylamide-containing Echinacea extracts were performed for various indications such as 
immunostimulation [119,120], for the treatment of common cold [121,122], as osteopathy treatment in 
children with recurrent otitis media [123], as prophilaxis for upper respiratory tract infections in 
children and acute respiratory illness [124].  
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Figure 8. Chemical structures of CB2 receptor agonists isolated from different natural sources 
 
CANNABINOID RECEPTOR ANTAGONIST 
CB1 receptor antagonists 
The CB1 receptor shows a key role in the control of food intake and energy balance. Several CB1 
receptor antagonist or inverse agonist were studied for treatment of obesity, diabetes and correlated 
cardio-metabolic problems. The biarylpyrazole derivative SR141716 (Fig. 9) known also as 
Rimonabant by Sanofi behaves as CB1 receptor antagonist with inverse agonist functional properties. 
When tested in humans, this compound showed to reduce body weight and to ameliorate dyslipidemias, 
diabetes, and metabolic syndrome [125]. Rimonabant was launched in Europe since 2006 but it was not 
approved by the US Food and Drug Administration. However in 2008 was withdrawn from the 
European market because of undesirable side effects, which comprised nausea, anxiety, depression, and 
in some cases, suicidal tendencies [126]. Since then, various inverse CB1 antagonists with similar 
pharmacological profiles were developed [26], such as SR147778 (Fig. 9), CP-945,598 (Fig. 9) and 
MK-0364 (Fig. 9) but their studies were stopped in the clinical phase because they exhibit the same 
typical side effects of Rimonabant. Interestingly, recent preclinical studies have demonstrated that 
Rimonabant, reduces the hypokinesia in an animal model of Parkinson disease at low dose [38].  
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Figure 9. Chemical structures of CB1 receptor antagonists 
 
In the last years various efforts to develop novel compounds with no or reduced side effect were made 
following two different approaches. The first was to develop CB1 receptor antagonists with no inverse 
agonist or weak inverse agonist properties. The best known of these compounds are AM4113 that is a 
pyrazole analog structurally related to Rimonabant, and AM6527 (Fig. 9) [127]. These compounds did 
not exhibit any of the undesirable side effects of inverse agonists in a number of animal models 
whereas they possess therapeutic effects typical of inverse CB1 receptor antagonists such as reduction 
in food consumption, weight loss, and capacity to antagonize the effects of stimulant and nicotine 
addiction [127].  
The development of peripherally active compounds represents another approach for obtaining CB1 
receptor antagonists with reduced undesirable side effects. It was demonstrated that the effects of these 
compounds involve the modulation in lipid metabolism and energy balance. The compound AM6545 
(Fig. 9) induces weight loss and improves lipid profile and insulin sensitivity [128]. Currently, this 
compound is in preclinical testing for the treatment of nonalcoholic fatty liver disease (NAFLD), as 
well as liver fibrosis [128].  
Recently a series of double amides based on the Rimonabant structure separated by an alkyl chain of 
several methylene units was reported. These compounds possess a different pharmacokinetic profile 
and thus reduced side effects. One of them, the compound N,N’-Heptan-1,7-diylbis[5-(4-
chlorophenyl)-1-(2,4- dichlorophenyl)-1H-pyrazole-3-carboxamide] (4d) (Fig. 9), was selected for  in 
vivo pharmacological evaluations. In particular its intraperitoneal administration resulted in a dose-
dependent inhibition of feeding indicating that, since this compound possesses a restricted brain-
penetrant, the appetite and weight reduction should be mediated by a mechanism involving leptin [129]. 
 
CB2 receptor antagonists 
At the present, very few compounds have been described as CB2-selective “neutral” antagonists, i.e. 
high-affinity ligands that lack significant inverse agonist action. CB2 neutral antagonist could be useful 
as a pharmacological “tool” to distinguish between tonic activity arising from endocannabinoid release 
(which it should oppose) and tonic “constitutive” activity of CB2 receptor (which it should not oppose). 
Recently biphenylic carboxamide derivative 10 (Fig. 10) [130] was described having such activity. 
Furthermore the 1,2-dihydro-2-oxopyridine-3-carboxamide 17 (Fig. 10) [131] was reported to show  
behaviour as CB2R neutral antagonist/weak partial inverse agonist. In particular it was reported that the 
functionality activity of the series of 1,2-dihydro-2-oxopyridine is controlled by the presence of  
substituent in position 5 of the heterocyclic nucleus.  
Several CB2 ligands with inverse agonist activity were reported in literature for treatment of various 
indications but often there is discrepancy in the reported data [132]. 
Very recently the biphenyl-phenyl-methanone derivative SMM-189 (Fig. 10) which is a potent and 
selective CB2 inverse agonist, showed to regulate microglial activation, in terms of chemokine 
expression and cell morphology [133]. Furthermore SMM-189 possesses acceptable biopharmaceutical 
properties indicating that this compound could be useful for the treatment of neurodegenerative 
disorders and traumatic brain injury [133].  
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Figure 10. Chemical structures of CB2 receptor antagonists/inverse agonists 
 
Current  & Future Development 
As a therapeutic target, the cannabinoid CB1 and CB2 receptors have found to date only modest 
success. However regarding cannabinoid CB1 receptor the development of CB1 agonists with reduced 
side effects through peripheralization could represent potential analgesic medications for treatment of 
pain. Furthermore the new peripherally-acting CB1 antagonist or brain penetrant neutral CB1 
antagonists could find usefulness for important disorders such as fat metabolism or those from opioids 
and alcohol. Allosteric modulators might offer an alternative strategy to pharmacologically modulate 
CB1 receptors in the brain without eliciting classic unwanted side effects. Finally CB2 agonists 
continue to be considered as potential medications for inflammatory and neuropathic pain, as well as in 
neurodegenerative conditions, including ALS, Huntington’s disease, Alzheimer’s disease, Parkinson’s 
disease, and multiple sclerosis. 
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